Six clinical trials have used either Zol, BrHPP, or 2M3B1PP to expand autologous Vγ9Vδ2 T cells ex vivo and these cells were directly infused (three trials with added IL-2 infusion and three without) for treatment of RCC (57–59), non-small cell lung cancer (NSCLC) (60, 61), and colorectal cancer (CRC) (62). Here, IL2 is linked to colorectal carcinoma.